Lancashire and South Cumbria
Formulary
Formulary
2 Cardiovascular system
02-12 Other lipid modifying agents
| Bempedoic acid with Ezetimibe Nustendi® |
|
Formulary
|
Tablets 180mg/10mg |
 NICE TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia |
|
| Bempedoic acid Nilemdo® |
|
Formulary
|
Tablets 180mg Where ezetimibe is not tolerated, Bempedoic acid may be used as monotherapy.
|
|
|
| Icosapent ethyl Vazkepa® |
|
Formulary
|
Capsules 998 mg |
|
NICE TA805: Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides |
|
| Inclisiran Leqvio® |
|
Formulary
|
Solution for injection pre-filled syringes 284mg/1.5ml Restricted to use in line with LSCMMG: Lipid Management Pathway for Secondary Prevention of Cardiovascular Disease (CVD). Included in NHS England HCD list to facilitate prescribing in secondary care until primary care prescribing is established. NHSE has introduced funding arrangements to allow prescribing in Primary Care for a nominal amount, see link below. |
 LSC Patient Pathway for Commencing Inclisiran NHSE: Funding and supply of inclisiran (Leqvio®) NICE TA733: Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia |
|
| Lomitapide capsules Lojuxta® |
|
Formulary
|
Capsules 5mg, 10mg, 20mg Under expert supervision |
|
NHSE: Clinical Commissioning Policy: Lomitapide for treating homozygous familial hypercholesterolaemia (adults) [1679] |
|
| Evinacumab Evkeeza® |
|
Formulary
|
Concentrate for solution for infusion vials 345mg/2.3ml |
|
NICE TA1002: Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over |
|
|
Links
- EMA recommends withdrawal of Tredapative
Enoxaparin for Treatment of Venous Thromboembolism **FOR USE IN THE BLACKPOOL REGION ONLY** - Enoxaparin Shared Care Guideline **FOR USE IN THE MORECAMBE BAY REGION ONLY**
- Low Molecular Weight Heparins - Use in Primary care Best Practice Guideline *FOR USE IN PENNINE REGION ONLY*
- LSC Hypertension in Adults: Diagnosis and Management
- LSC Patient Pathway for Commencing Inclisiran
- LSC Patient Pathway for Commencing Inclisiran
- LSC Patient Pathway for Commencing Inclisiran
- LSC Statin Intolerance Pathway
- LSC Statin Intolerance Pathway
- LSCMMG: Atrial Fibrillation Pathway for the prevention of stroke and systemic embolism in AF in the absence of valvular heart disease
- LSCMMG: Colesevelam for Cardiovascular Disease (CVD) prevention NMR
- LSCMMG: Evolocumab NMR
- LSCMMG: Fenofibrate NMR
- LSCMMG: Lipid Management Pathway for Primary Prevention of Cardiovascular Disease
- LSCMMG: Lipid Management Pathway for Primary Prevention of Cardiovascular Disease
- LSCMMG: Lipid Management Pathway for Secondary Prevention of Cardiovascular Disease
- LSCMMG: Lipid Management Pathway for Secondary Prevention of Cardiovascular Disease
- MHRA: Fibrates: first-line treatment not recommended
- MHRA: Fibrates: first-line treatment not recommended
- MHRA: Statins: interactions, and updated advice for atorvastatin
- MHRA: Statins: interactions, and updated advice for atorvastatin
- MHRA: Statins: risk of hyperglycaemia and diabetes
- MHRA: Statins: very infrequent reports of myasthenia gravis
- NHSE: Clinical Commissioning Policy: Lomitapide for treating homozygous familial hypercholesterolaemia (adults) [1679]
- NHSE: Funding and supply of inclisiran (Leqvio®)
- NHSE: Summary of national guidance for lipid management
- NICE HST13: Volanesorsen for treating familial chylomicronaemia syndrome
- NICE NG106: Chronic heart failure in adults: diagnosis and management
- NICE NG136: Hypertension in adults: diagnosis and management
- NICE NG185: Acute Coronary Syndromes
- NICE NG187: Acute heart failure: diagnosis and management
- NICE NG196: Atrial fibrillation: diagnosis and management
- NICE NG203: Chronic kidney disease: assessment and management
- NICE NG238: Cardiovascular disease: risk assessment and reduction, including lipid modification
- NICE NG242: Diabetic retinopathy: management and monitoring
- NICE NG95: Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis
- NICE TA1002: Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over
- NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
- NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
- NICE TA733: Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
- NICE TA805: Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides
- NICE: schizophrenia - omega-3 fatty acid medicines
- NICE: schizophrenia - omega-3 fatty acid medicines
- Policy and procedure for prophylaxis against, and treatment of, VTE in adult patients **FOR USE IN THE CENTRAL LANCS REGION ONLY**
- Prevention of VTE in Medical Surgical Patients (16 years +) and those requiring lower limb plaster casts/immobilisations **FOR USE IN THE BLACKPOOL REGION ONLY**
- Renal: Enhanced Supportive Kidney Care Guideline
- UKMI Q & A: Review of evidence for dyslexia